Q1 2025 Earnings Call Transcript May 9, 2025 Operator: Greetings and welcome to the Collegium Pharmaceutical First Quarter ...

Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million, adjusted non-GAAP EBITDA of $195.0 ...

Discover key insights from Collegium Pharmaceutical's Q1 2025 earnings call: 23% revenue growth, Jornay PM's market success, sales force expansion & ...

Leaders from Salix Pharmaceuticals and Syneos Health Communications share their real-world journeys to becoming truly ...

Operator: Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants ...

Sales and operating profit growth, significant product acquisition completed, 11 new products, first deal outside Europe and graduation year passed January - March 2025 Consolidated sales during the ...

The heavily pre-treated patients showed median progression-free survival of 29 months, which meant their tumours didn’t get ...

Johnson & Johnson has generated evidence that the pace of oncology innovation is overwhelming physicians. | Johnson & Johnson ...

Egham, UK - 6th May 2025 - Essential Pharma ("Essential” or "the Company”), a global pharmaceutical company developing and ...

Paysign's patient affordability segment is experiencing rapid growth with higher margins, and is expected to double revenue ...

The Supreme Court has said doctors should prescribe only generic drugs. The court made the remark while hearing a PIL seeking ...

Doctors across the country should be mandated to prescribe only generic medicines instead of brand names, the Supreme Court ...